BioSpace News Archive

Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 32 nd Annual Virtual Healthcare Conference taking place December 1-3, 2020. The pre-recorded fireside chat will be accessible beginning at 10 a.m. Easter

Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled “Anti-virus Agent and Method for Treatment of Viral Infection” , furthering marketing and manufacturing monopolies to February 2037. “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented

ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. From November 23 to December 3, 2020 , a fireside chat recording will be

Beckman Coulter, a clinical diagnostics leader, today launched its Access SARS-CoV-2 IgG II assay that measures a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December: Evercore ISI 3 rd Annual HealthCONx Conference Fireside chat and an open Q&A: T

The Progeria Research Foundation announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher.

Despite an increasing need for COVID-19 care, hospitals are facing financial pressures due to the decline in outpatient and non-emerging procedures.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not

Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today reported that its wholly owned Canadian subsidiary, Artelo Biosciences Corporation, and Dr. Steven Laviolette’s laboratory at the University of Western Ontario, have been awarded a Mitacs Accelerate grant.